Ironwood and Allergan Receive Notices of Allowance for Patent Applications Covering 72 mcg Dose of LINZESS® (linaclotide)
Ironwood Pharmaceuticals, Inc. - Class A (IRWD)
Last ironwood pharmaceuticals, inc. - class a earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investor.ironwoodpharma.com
Company Research
Source: Business Wire
– New patents expected to provide coverage for 72 mcg dose into 2031 – BOSTON--(BUSINESS WIRE)--Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD) announced today that the United States Patent and Trademark Office (USPTO) has issued Notices of Allowance for patent applications covering the formulation of the 72 mcg dose of LINZESS® (linaclotide) and methods of using the formulation. The patent applications are expected to issue in 2020 and expire in 2031.LINZESS is approved and marketed in the United States for the treatment of adult men and women suffering from irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC). It was the first guanylate cyclase-C (GC-C) agonist to be approved by the U.S. Food and Drug Administration.“We believe that this action by the USPTO reinforces the durability of our flagship product LINZESS, the number one prescribed medication for millions of adult patients with IBS-C or CIC,” said Mark Mallon, chief executive officer
Show less
Read more
Impact Snapshot
Event Time:
IRWD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IRWD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IRWD alerts
High impacting Ironwood Pharmaceuticals, Inc. - Class A news events
Weekly update
A roundup of the hottest topics
IRWD
News
- Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Craig Hallum from a "hold" rating to a "strong-buy" rating.MarketBeat
- Ironwood Pharmaceuticals (NASDAQ:IRWD) had its price target raised by analysts at Wells Fargo & Company from $3.00 to $5.00. They now have an "equal weight" rating on the stock.MarketBeat
- Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citizens Jmp from a "market perform" rating to a "market outperform" rating. They now have a $8.00 price target on the stock.MarketBeat
- Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Citigroup Inc. from a "market perform" rating to an "outperform" rating.MarketBeat
- Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by analysts at Zacks Research from a "hold" rating to a "strong-buy" rating.MarketBeat
IRWD
Earnings
- 11/10/25 - Beat
IRWD
Sec Filings
- 1/7/26 - Form 4
- 1/5/26 - Form 144
- 1/2/26 - Form 8-K
- IRWD's page on the SEC website